NASDAQ:NVCNNeovasc Stock Price, Forecast & News

Neovasc's stock was trading at $2.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVCN stock has increased by 49.3% and is now trading at $3.30. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neovasc.

Neovasc is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Neovasc.

Neovasc Inc (NASDAQ:NVCN) posted its earnings results on Thursday, May, 7th. The medical equipment provider reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.17. The medical equipment provider earned $0.53 million during the quarter, compared to the consensus estimate of $0.60 million. View Neovasc's earnings history.

Neovasc shares reverse split on the morning of Friday, September 21st 2018. The 1-100 reverse split was announced on Tuesday, September 11th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 20th 2018. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 1 shares after the split.

3 brokers have issued 1 year price targets for Neovasc's shares. Their forecasts range from $3.00 to $15.00. On average, they expect Neovasc's stock price to reach $7.67 in the next twelve months. This suggests a possible upside of 132.3% from the stock's current price. View analysts' price targets for Neovasc.

News articles about NVCN stock have trended somewhat positive this week, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neovasc earned a news impact score of 1.0 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutNeovasc.

Neovasc saw a increase in short interest in May. As of May 15th, there was short interest totaling 244,800 shares, an increase of 18.6% from the April 30th total of 206,400 shares. Based on an average daily trading volume, of 216,200 shares, the days-to-cover ratio is currently 1.1 days. Currently, 2.4% of the shares of the stock are short sold. View Neovasc's Current Options Chain.

Some companies that are related to Neovasc include T2 Biosystems (TTOO), Restoration Robotics (HAIR), BeyondAirInc . (XAIR), Venus Concept (VERO), Spectral Medical (EDTXF), PAVmed (PAVM), Titan Medical (TMDI), SANUWAVE Health (SNWV), AIT Therapeutics (AITB), BRAINSWAY LTD/S (BWAY), Pro-Dex (PDEX), Nephros (NEPH), Nephros (NEPHD), Sensus Healthcare (SRTS) and STRATA Skin Sciences (SSKN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP), Amicus Therapeutics (FOLD), Protalix Biotherapeutics (PLX), 22nd Century Group (XXII), Immune Pharmaceuticals (IMNP), Advanced Micro Devices (AMD) and Amarin (AMRN).

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Neovasc's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Capital World Investors (5.78%), Magnetar Financial LLC (4.28%), Morgan Stanley (0.57%) and Two Sigma Advisers LP (0.35%).

NVCN stock was sold by a variety of institutional investors in the last quarter, including Magnetar Financial LLC.

NVCN stock was bought by a variety of institutional investors in the last quarter, including Capital World Investors, Morgan Stanley, and Two Sigma Advisers LP.

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCN stock can currently be purchased for approximately $3.30.

Neovasc has a market capitalization of $38.97 million and generates $2.09 million in revenue each year. The medical equipment provider earns $-35,130,000.00 in net income (profit) each year or ($5.05) on an earnings per share basis. Neovasc employs 98 workers across the globe.

The official website for Neovasc is www.neovasc.com.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-248-4138 or via email at [email protected]